FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gerhard Nehmiz

Research Profile

Disorders

Hepatitis C, Chronic

Chemicals & Drugs

Procedures

Concepts & Ideas

Living Beings

Hepacivirus

Physiology

Genotype

Co-author Network

Publications

TOP 3
Sebastian Härtter; Gerhard Nehmiz; Regina Sennewald; Paul Reilly
Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects.
Sebastian Härtter; Michael Koenen-Bergmann; Ute Lemke; Gerhard Nehmiz; Ashish Sharma; Wolfgang Timmer; Paul A Reilly
Response to the letter by Dr Chin and co-workers.
Sebastian Härtter; Michael Koenen-Bergmann; Ute Lemke; Gerhard Nehmiz; Ashish Sharma; Wolfgang Timmer; Paul A Reilly
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gerhard Nehmiz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sebastian Härtter; Gerhard Nehmiz; Regina Sennewald; Paul Reilly
Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects.
British journal of clinical pharmacology 2013;75(4):1053-62.
2013: Sebastian Härtter; Michael Koenen-Bergmann; Ute Lemke; Gerhard Nehmiz; Ashish Sharma; Wolfgang Timmer; Paul A Reilly
Response to the letter by Dr Chin and co-workers.
British journal of clinical pharmacology 2013;75(2):556.
2012: Sebastian Härtter; Michael Koenen-Bergmann; Ute Lemke; Gerhard Nehmiz; Ashish Sharma; Wolfgang Timmer; Paul A Reilly
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.
British journal of clinical pharmacology 2012;74(3):490-500.
2011: Stefan Zeuzem; Fabien Zoulim; Peter Angus; Keikawus Arastéh; Tarik Asselah; Jean-Pierre Bronowicki; Ed Gane; Carla Haefner; Markus Heim; George Kukolj; Dominique Larrey; Ansgar Lohse; Beat Müllhaupt; Gerhard Nehmiz; Stanislas Pol; Stuart Roberts; Marcus Schuchmann; Jerry O Stern; Jean-Pierre Zarski; Wulf Otto Boecher
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
Gastroenterology 2011;141(6):2047-55; quiz e14.
2009: Andreas Erhardt; Katja Deterding; Yves Benhamou; Markus Reiser; Xavier Forns; Stanislas Pol; José Luis Calleja; Susanne Ross; Hans Christian Spangenberg; Javier Garcia-Samaniego; Michael Fuchs; Jaime Enríquez; Johannes Wiegand; Jerry Stern; Kate Wu; George Kukolj; Martin Marquis; Pierre Beaulieu; Gerhard Nehmiz; Jürgen Steffgen
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment.
Antiviral therapy 2009;14(1):23-32.
2007: Michael D Ezekowitz; Paul A Reilly; Gerhard Nehmiz; Timothy A Simmers; Rangadham Nagarakanti; Kambiz Parcham-Azad; K Erik Pedersen; Dominick A Lionetti; Joachim Stangier; Lars Wallentin
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).
The American journal of cardiology 2007;100(9):1419-26.
2006: Eva Herrmann; Stefan Zeuzem; Christoph Sarrazin; Holger Hinrichsen; Yves Benhamou; Michael P Manns; Markus Reiser; Henk W Reesink; José L Calleja; Xavier Forns; Gerhard G Steinmann; Gerhard Nehmiz
Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.
Antiviral therapy 2006;11(3):371-6.
2005: Joachim Stangier; Bengt I Eriksson; Ola E Dahl; Lennart Ahnfelt; Gerhard Nehmiz; Hildegard Stähle; Karin Rathgen; Robbyna Svärd
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
Journal of clinical pharmacology 2005;45(5):555-63.
2005: Markus Reiser; Holger Hinrichsen; Yves Benhamou; Henk W Reesink; Heiner Wedemeyer; Cristina Avendano; Neus Riba; Chan-Loi Yong; Gerhard Nehmiz; Gerhard G Steinmann
Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
Hepatology (Baltimore, Md.) 2005;41(4):832-5.
2004: Holger Hinrichsen; Yves Benhamou; Heiner Wedemeyer; Markus Reiser; Roel E Sentjens; José L Calleja; Xavier Forns; Andreas Erhardt; Jens Crönlein; Ricardo L Chaves; Chan-Loi Yong; Gerhard Nehmiz; Gerhard G Steinmann
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.
Gastroenterology 2004;127(5):1347-55.
2004: Bengt I Eriksson; Ola E Dahl; Lennart Ahnfelt; Peter Kälebo; Joachim Stangier; Gerhard Nehmiz; K Hermansson; V Kohlbrenner
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
Journal of thrombosis and haemostasis : JTH 2004;2(9):1573-80.
2004: Brian Guth; Hans Narjes; Hans-Dieter Schubert; Paul Tanswell; Axel Riedel; Gerhard Nehmiz
Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects.
British journal of clinical pharmacology 2004;58(1):40-51.
2000: H Narjes; Gerhard Nehmiz
Effect of hospitalisation on liver enzymes in healthy subjects.
European journal of clinical pharmacology 2000;56(4):329-33.